Bicara Therapeutics Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Bicara Therapeutics Inc. (BCAX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$689.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Bicara Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.40M.
- Bicara Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$2.09M.
- Bicara Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$839.00K, a 105.06% decline year-over-year.
- Bicara Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $301.00K, a 178.70% increase year-over-year.
- Bicara Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$5.28M, a 131.34% decline from fiscal 2024.
- Bicara Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $16.85M, a 1743.54% increase from fiscal 2023.
- Bicara Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $914.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$689.00K 10-Q · filed 2026-08-11 | -$1.53M derived: sum of 3 quarters · filed 2026-08-11 | -$1.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$2.09M 10-Q · filed 2026-05-11 | -$2.93M derived: sum of 2 quarters · filed 2026-05-11 | -$2.63M derived: sum of 3 quarters · filed 2026-05-11 | -$3.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$538.00K derived: sum of 2 quarters · filed 2026-03-30 | -$1.17M derived: sum of 3 quarters · filed 2026-08-11 | -$5.28M 10-K · filed 2026-03-30 |
| 2025-09-30 | $301.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$326.00K derived: sum of 2 quarters · filed 2026-08-11 | -$4.44M 10-Q · filed 2025-11-10 | $12.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$627.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.74M 10-Q · filed 2026-08-11 | $11.83M derived: sum of 3 quarters · filed 2026-08-11 | $11.94M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$4.12M 10-Q · filed 2026-05-11 | $12.45M derived: sum of 2 quarters · filed 2026-05-11 | $12.56M derived: sum of 3 quarters · filed 2026-05-11 | $12.50M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $16.68M derived: sum of 2 quarters · filed 2026-03-30 | $16.61M derived: sum of 3 quarters · filed 2026-03-30 | $16.85M 10-K · filed 2026-03-30 |
| 2024-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $45.00K derived: sum of 2 quarters · filed 2025-11-10 | $280.00K 10-Q · filed 2025-11-10 | $339.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $172.00K 10-Q · filed 2025-08-12 | $231.00K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $235.00K 10-Q · filed 2025-05-13 | $294.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $914.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $855.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |